A. Wojdan et al., Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and in vivo bladder instability in rat, J PHARM EXP, 289(3), 1999, pp. 1410-1418
Citations number
37
Categorie Soggetti
Pharmacology & Toxicology
Journal title
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
The effects of the ATP-dependent potassium channel agonists ZD6169, celikal
im, and WAY-133537 on bladder contractile function were examined in vitro o
n isolated bladder strips and in vivo on spontaneous bladder contractions.
All three compounds produced a concentration-dependent relaxation of isolat
ed rat detrusor strips (IC50 values = 0.93, 0.03, and 0.09 mu M, respective
ly for ZD6169, celikalim, and WAY-133537. Contractile inhibition by all thr
ee compounds was fully reversed by 6 mu M glyburide. These compounds also e
ffectively inhibited spontaneous bladder contractions in the rat hypertroph
ied bladder model of detrusor instability. We also examined the electrophys
iological properiies of WAY-133537 on isolated rat bladder detrusor myocyte
s. Myocytes had an average resting membrane potential of -40 mV. Under patc
h current-clamp conditions, WAY-133537 (0.3 and 1.0 mu M, n = 4-5) produced
a significant hyperpolarization of 21 and 26 mV, respectively. Hyperpolari
zation was reversed by the addition of 5 mu M glyburide. In patch voltage-c
lamp studies, WAY-133537 (0.3 mu M, n = 3) significantly increased outward
current in response to both voltage step and ramp protocols consistent with
activation of the ATP-dependent potassium channel. In the detrusor instabi
lity model, WAY-133537 and celikalim had similar oral potencies (ED50 = 0.1
3 and 0.3 mg/kg, respectively), whereas ZD6169 was less potent (ED50 = 2.4
mg/kg). The antihypertensive agent celikalim exerted effects on the bladder
at doses that significantly reduced systemic blood pressure. In contrast,
both WAY-133537 and ZD6169 inhibited bladder hyperactivity at doses that pr
oduced minimal changes in both mean arterial blood pressure and heart rate.
These data suggest that both WAY-133537 and ZD6169 may be useful in the tr
eatment of bladder instability at doses associated with minimal hemodynamic
side effects.